Weight Loss & GLP-1s

Why GLP-1s Support Healthy Weight Loss

GLP-1 medications like semaglutide and tirzepatide mimic a natural hormone that helps regulate appetite, blood sugar, and digestion. They slow how quickly food leaves the stomach, increase feelings of fullness, and reduce cravings—making it easier to achieve sustainable weight loss without extreme dieting.

In a dermatology or medical aesthetics practice, GLP-1 therapy complements cosmetic care by improving overall wellness, body contour, and skin appearance. As patients lose weight, they often notice healthier skin tone, reduced inflammation, and enhanced results from aesthetic procedures—creating a more balanced, natural, and confident look.

Semaglutide vs. Tirzepatide

Woman in white bikini with arms raised on a sandy beach facing the ocean

  • Semaglutide (brands include Ozempic®, Wegovy®, Rybelsus®) is a GLP-1 receptor agonist used for type 2 diabetes and, in some products, chronic weight management. Semaglutide (GLP-1 RA) helps regulate appetite and glucose by enhancing glucose-dependent insulin secretion and slowing gastric emptying.

  • Tirzepatide (brands include Mounjaro®, Zepbound®) is a dual GIP/GLP-1 receptor agonist for type 2 diabetes and chronic weight management. Tirzepatide (GIP + GLP-1 RA) targets both GIP and GLP-1 receptors, which can improve glycemic control and support weight management, per labeling. 


Schedule a Consultation

GLP-1
FAQs

  • Both semaglutide (sold under brands like Wegovy and Ozempic) and tirzepatide (sold under brands like Mounjaro and Zepbound) are GLP-1 receptor agonists.

    These medications were originally developed for Type 2 Diabetes Management and help regulate blood sugar and appetite, which has made them highly effective tools for medically supervised weight loss.

    Both medications have undergone extensive clinical testing and long-term follow-ups for diabetes and obesity management, showing sustained efficacy and manageable side effect profiles even when compounded by reputable, trusted pharmacies.

  • Ozempic and Mounjaro, among others, refer to the FDA-approved formulations of semaglutide and tirzepatide prescribed for Type 2 diabetics or chronic weight-loss management patients.

    When used in a cosmetic setting, the same active ingredients are prescribed under physician supervision for off-label aesthetic weight reduction, adhering to clinical safety protocols.

  • Semaglutide activates the GLP-1 receptor only.

    Tirzepatide activates both GLP-1 and GIP receptors, offering a dual mechanism that can lead to slightly greater average weight loss.

  • GLP-1s mimic a natural gut hormone that slows digestion and increases feelings of fullness after eating. This helps reduce calorie intake and curb cravings.

    Clinical studies show average weight loss of 10-20% of body weight when combined with diet and exercise under medical supervision.

  • Adults with a BMI <30 (or <27 with a weight-related condition such as high blood pressure or prediabetes) may be candidates.

    Patients should be evaluated by a licensed provider to rule out contraindications like thyroid C-cell tumors, MEN2, or certain gastrointestinal conditions.

  • Semaglutide and Tirzepatide are delivered as once-weekly subcutaneous injections. Your provider will instruct you on proper use, rotation of injection sites, and dose titration to minimize nausea and other common side effects.

  • The most commonly reported side effects are nausea, diarrhea, constipation, abdominal discomfort, and decreased appetite.

    These symptoms are typically temporary and improve as your body adjusts.

    Staying hydrated and eating smaller meals may help to reduce discomfort.

  • GLP-1 medications support sustainable lifestyle change, but weight regain can occur if therapy is stopped without continued nutritional and behavioral support.

    For best results, use under a comprehensive medical weight management plan with ongoing monitoring and maintenance strategies.

  • Most patients begin noticing changes in appetite and body composition within 4-6 weeks with significant results typically seen after 3-6 months of continued use, depending on dosage, lifestyle, and metabolism.

  • Indirectly, yes. Weight loss can define facial contours, reduce inflammation, and enhance skin clarity amplifying the results of aesthetic procedures like fillers, Kybella, or skin tightening lasers.

    However, rapid fat loss may also cause mild skin laxity, which can be addressed through aesthetic dermatology treatments such as fillers, skin tightening lasers, or collagen-induction therapies.